Mitoxantrone is a Topoisomerase II Inhibitor for Leukemia Research
Chronic lymphocytic leukemia (CLL) is the most common type of leukemia, which defined as a minimum of 5 × 109/L monoclonal B cells in the blood. However, CLL affects approximately…
Chronic lymphocytic leukemia (CLL) is the most common type of leukemia, which defined as a minimum of 5 × 109/L monoclonal B cells in the blood. However, CLL affects approximately…
Microtubules act as "railroads" that drive intracellular transport in cells. Specifically, they interact with auxiliary proteins to assemble into larger structures and provide a framework for the rest of the…
Hydroxyurea, also known as hydroxycarbamide, is a straightforward compound. The compound boasts a molecular formula of CH4N2O2. Intriguingly, it bears a structural resemblance to urea. Pioneers first synthesized this compound…
Disulfiram (DSF) is a drug for the treatment of chronic alcoholism. It first received pharmacological attention in 1880, when it was used externally to treat itch. For the treatment of…
Peripheral T-cell lymphomas (PTCL) are malignancies derived from mature (post-thymic) T cells and natural killer cells. As a rare and aggressive type of non-Hodgkin’s lymphoma, PTCL affects mature T cells.…
The tumor microenvironment (TME) serves as the internal space for tumor cell growth and progression. Contrary to traditional viewpoints, we now perceive the TME as a complex integrated system. This…
mTOR is a serine/threonine kinase that regulates cell growth, metabolism, proliferation, and survival. In addition, mTOR complex-1 (mTORC1) and mTOR complex-2 (mTORC2) are critical mediators of the PI3K-AKT pathway, which…
Subclass I of the receptor tyrosine kinase (RTK) superfamily consists of the ERBB or epidermal growth factor (EGF) receptors. In humans, the family includes Her1 (EGFR, ERBB1), Her2 (ERBB2), Her3…
CXCR4 is a chemokine receptor mainly located on the cell membrane of CD34+ cells and various inflammatory cells. SDF-1α/CXCL12 (chemokine stromal cell-derived factor 1 α) is a ligand of CXCR4. It…
On November 27, 2023, the Food and Drug Administration approved Nirogacestat for adult patients with progressing desmoid tumors who require systemic treatment. Nirogacestat blocks the activity of an enzyme called…